2022. Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. Biomolecules and Biomedicine. 22, 2 (Apr. 2022), 300–301. DOI:https://doi.org/10.17305/bjbms.2021.6419.